Literature DB >> 2846659

Antibodies to parathyroid hormone-related protein lower serum calcium in athymic mouse models of malignancy-associated hypercalcemia due to human tumors.

S C Kukreja1, D H Shevrin, S A Wimbiscus, P R Ebeling, J A Danks, C P Rodda, W I Wood, T J Martin.   

Abstract

A parathyroid hormone-related protein (PTHrP) has recently been isolated from tumors associated with hypercalcemia. In the present study, we tested the effects of neutralizing antisera to the PTHrP on serum calcium and urine cAMP in two animal models of malignancy-associated hypercalcemia. The animal models consisted of (a) a human squamous cell lung cancer and (b) a human laryngeal cancer, both serially carried in athymic mice. The antisera specifically reduced the elevated serum calcium and urinary cAMP levels in the tumor-bearing animals. We conclude that PTHrP plays a major role in the pathogenesis of malignancy-associated hypercalcemia.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2846659      PMCID: PMC442751          DOI: 10.1172/JCI113794

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  29 in total

1.  Effect of passive immunization with an antiserum to thyrotropin (TSH)-releasing hormone on plasma TSH levels in thyroidectomized rats.

Authors:  M Szabo; N Kovathana; K Gordon; L A Frohman
Journal:  Endocrinology       Date:  1978-03       Impact factor: 4.736

2.  The unlabeled antibody enzyme method of immunohistochemistry: preparation and properties of soluble antigen-antibody complex (horseradish peroxidase-antihorseradish peroxidase) and its use in identification of spirochetes.

Authors:  L A Sternberger; P H Hardy; J J Cuculis; H G Meyer
Journal:  J Histochem Cytochem       Date:  1970-05       Impact factor: 2.479

3.  Urinary and nephrogenous adenosine 3',5'-monophosphate in the hypercalcemia of malignancy.

Authors:  R K Rude; C F Sharp; R S Fredericks; S B Oldham; N Elbaum; J Link; L Irwin; F R Singer
Journal:  J Clin Endocrinol Metab       Date:  1981-04       Impact factor: 5.958

4.  Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and nonhumoral groups.

Authors:  A F Stewart; R Horst; L J Deftos; E C Cadman; R Lang; A E Broadus
Journal:  N Engl J Med       Date:  1980-12-11       Impact factor: 91.245

Review 5.  The hypercalcemia of cancer. Clinical implications and pathogenic mechanisms.

Authors:  G R Mundy; K J Ibbotson; S M D'Souza; E L Simpson; J W Jacobs; T J Martin
Journal:  N Engl J Med       Date:  1984-06-28       Impact factor: 91.245

6.  Elevated nephrogenous cyclic AMP with normal serum parathyroid hormone levels in patients with lung cancer.

Authors:  S C Kukreja; W P Shemerdiak; T E Lad; P A Johnson
Journal:  J Clin Endocrinol Metab       Date:  1980-07       Impact factor: 5.958

7.  Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: uncoupling of bone cell activity.

Authors:  A F Stewart; A Vignery; A Silverglate; N D Ravin; V LiVolsi; A E Broadus; R Baron
Journal:  J Clin Endocrinol Metab       Date:  1982-08       Impact factor: 5.958

8.  A model for malignancy-associated humoral hypercalcemia.

Authors:  E C Abramson; L J Kukla; D H Shevrin; T E Lad; W P McGuire; S C Kukreja
Journal:  Calcif Tissue Int       Date:  1984-09       Impact factor: 4.333

9.  Direct stimulation of bone resorption by epidermal growth factor.

Authors:  L G Raisz; H A Simmons; A L Sandberg; E Canalis
Journal:  Endocrinology       Date:  1980-07       Impact factor: 4.736

10.  Quantitative bone histomorphometry in nude mice bearing a human squamous cell lung cancer.

Authors:  S C Kukreja; T J Rosol; D H Shevrin; P A York
Journal:  J Bone Miner Res       Date:  1988-06       Impact factor: 6.741

View more
  16 in total

Review 1.  Hypercalcemia of malignancy.

Authors:  V Grill; T J Martin
Journal:  Rev Endocr Metab Disord       Date:  2000-11       Impact factor: 6.514

2.  Endothelin-1 and osteoblastic metastasis.

Authors:  Gregory R Mundy
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-08       Impact factor: 11.205

Review 3.  Hypercalcaemia in malignancy.

Authors:  D A Heath
Journal:  BMJ       Date:  1989-06-03

Review 4.  Parathyroid hormone-like peptide.

Authors:  Daniel J Drucker
Journal:  Endocr Pathol       Date:  1991-03       Impact factor: 3.943

5.  Guanosine nucleotides inhibit different syndromes of PTHrP excess caused by human cancers in vivo.

Authors:  Wolfgang E Gallwitz; Theresa A Guise; Gregory R Mundy
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

6.  Humoral hypercalcemia of malignancy: severe combined immunodeficient/beige mouse model of adult T-cell lymphoma independent of human T-cell lymphotropic virus type-1 tax expression.

Authors:  V Richard; M D Lairmore; P L Green; G Feuer; R S Erbe; B Albrecht; C D'Souza; E T Keller; J Dai; T J Rosol
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

Review 7.  Anorexia in human and experimental animal models: physiological aspects related to neuropeptides.

Authors:  Mitsuhiro Yoshimura; Yasuhito Uezono; Yoichi Ueta
Journal:  J Physiol Sci       Date:  2015-06-30       Impact factor: 2.781

8.  NOD/SCID mouse model of canine T-cell lymphoma with humoral hypercalcaemia of malignancy: cytokine gene expression profiling and in vivo bioluminescent imaging.

Authors:  M V P Nadella; W C Kisseberth; K S Nadella; N K Thudi; D H Thamm; E A McNiel; A Yilmaz; K Boris-Lawrie; T J Rosol
Journal:  Vet Comp Oncol       Date:  2008-03       Impact factor: 2.613

Review 9.  Hypercalcemia in malignancy.

Authors:  G J Strewler; R A Nissenson
Journal:  West J Med       Date:  1990-12

Review 10.  PTH receptor-1 signalling-mechanistic insights and therapeutic prospects.

Authors:  Ross W Cheloha; Samuel H Gellman; Jean-Pierre Vilardaga; Thomas J Gardella
Journal:  Nat Rev Endocrinol       Date:  2015-08-25       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.